Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shanghai Heartcare Medical Technology Corp. Ltd. Class H ( (HK:6609) ) has shared an announcement.
In 2024, Shanghai Heartcare Medical Technology Corp. Ltd. reported a 19.6% increase in revenue to RMB277.9 million, despite a decrease in gross profit margin due to competitive pricing pressures. The company’s loss before tax significantly decreased by 88.3%, attributed to cost control and efficiency measures. The company is focusing on the development and sales of neuro-intervention devices, with notable increases in sales volumes for stroke treatment devices. It has also achieved regulatory approvals for new products and is expanding its international market reach with multiple product registrations and certifications.
More about Shanghai Heartcare Medical Technology Corp. Ltd. Class H
Shanghai Heartcare Medical Technology Corp. Ltd. is a company based in China that specializes in neuro-intervention treatment devices. Its primary products include thrombectomy stents, distal access catheters, aspiration catheters, and support catheters, focusing on treatments for acute ischemic and hemorrhagic strokes. The company is actively expanding its market presence both domestically and internationally.
YTD Price Performance: 44.87%
Average Trading Volume: 51,152
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.23B
For a thorough assessment of 6609 stock, go to TipRanks’ Stock Analysis page.